51
R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
2024
2024
Volltext
Weitere Treffer
52
R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
2024
2024
Volltext
Weitere Treffer
53
R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
2024
2024
Volltext
Weitere Treffer
54
R. J. S. D. Heine, F. W. Thielen, R. H. J. Mathijssen, R. W. F. van Leeuwen, M. G. Franken, C. A. Uyl-de Groot
2024
2024
Volltext
Weitere Treffer
Suche einschränken
C. A. Uyl-de Groot
150
F. W. Thielen
150
M. G. Franken
150
R. H. J. Mathijssen
150
R. J. S. D. Heine
150
R. W. F. van Leeuwen
150
Contino, Francesco
37
Limpens, Gauthier
37
Rixhon, Xavier
27
Diederik Coppitters
25
Meers, Erik
17
Coppitters, Diederik
16
Jeanmart, Hervé
16
Janssens, Arnold
15
Postma, M.J.
15
Francesco Contino
14
Gauthier Limpens
14
Hervé Jeanmart
14
Xavier Rixhon
14
Beyers, Miriam
12
Bruun, Sander
12
Ravi, Rahul
12
Jeanmart, Hervé
11
Bia, Michela
10
Bianchini, Juana
10
Cargnel, Mickael
10
Cornélusse, Bertrand
10
De Boer, Anthonius
10
De Clercq, Kris
10
Delforge, Damien
10
Dubois, Antoine
10
Dumas, Jonathan
10
Flores-Lagunes, Alfonso
10
Humblet, Marie-France
10
Jacques, Pierre
10
Jun Huang
10
Koenders, Jolanda M. A.
10
Koenen, Frank
10
Laverge, Jelle
10
Linssen, Gerard C. M.
10
Meeder, Joan G.
10
Mercatanti, Andrea
10
Pattyn, Xavier
10
Postma, Maarten J.
10
Ramos, Isaac Corro
10
Rutten-van Molken, Maureen P. M. H.
10
Saegerman, Claude
10
Souverein, Patrick C.
10
Thiran, Paolo
10
Van Der Stede, Yves
10
Biotechnology
155
Science Policy
155
&# 8364
150
>
150
> expanding
150
Cancer
150
Computational Biology
150
Ecology
150
Infectious Diseases
150
Plant Biology
150
already approved immuno
150
assumed lower r
150
based prices
150
based pricing
150
based pricing model
150
based pricing models
150
consistently lower
150
cumulative indication
150
daratumumab &# 8217
150
daratumumab </ p
150
daratumumab per vial
150
deterministic stepwise analysis
150
dutch list prices
150
eligible patient population
150
indication (&# 8364
150
indication broadening
150
indication expansion
150
indications due
150
initial r
150
initial years
150
l &# 246
150
larger patient populations
150
lower estimates resulted
150
model proposed
150
modeled cbps depending
150
ongoing discussions
150
pembrolizumab (&# 8364
150
pembrolizumab per vial
150
pharmaceutical pricing
150
potential effect
150
profit margin
150
profit margin contributed
150
registered indications
150
scenario analysis
150
sensitivity analysis showed
150
significant impact
150
significant influence
150
smaller patient populations
150
study focuses
150
xlink \
150